Kura Oncology Appoints New CMO, CSO, and Directors
Ticker: KURA · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $40,000, $7,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition
TL;DR
Kura Oncology beefs up exec team & board with new CMO, CSO, and directors.
AI Summary
Kura Oncology, Inc. announced on September 13, 2024, changes in its executive team and board of directors. Specifically, Dr. Michael J. Grey was appointed as Chief Medical Officer, and Dr. Steven M. De Jong was appointed as Chief Scientific Officer. Additionally, the company elected two new directors, Ms. Sarah E. Kelly and Mr. David M. R. Johnson, to its Board of Directors.
Why It Matters
These executive and board changes could signal a strategic shift or a renewed focus on specific areas of the company's drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- Dr. Michael J. Grey (person) — Appointed Chief Medical Officer
- Dr. Steven M. De Jong (person) — Appointed Chief Scientific Officer
- Ms. Sarah E. Kelly (person) — Elected Director
- Mr. David M. R. Johnson (person) — Elected Director
- September 13, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer at Kura Oncology?
Dr. Michael J. Grey has been appointed as the new Chief Medical Officer.
What is the new role of Dr. Steven M. De Jong?
Dr. Steven M. De Jong has been appointed as the new Chief Scientific Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 13, 2024.
How many new directors were elected to Kura Oncology's Board?
Two new directors, Ms. Sarah E. Kelly and Mr. David M. R. Johnson, were elected.
What is the principal executive office address for Kura Oncology?
The address is 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.
Filing Stats: 697 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-17 16:05:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
- $40,000 — receive an (a) annual cash retainer of $40,000 for service on the Board and (b) additi
- $7,500 — (b) additional annual cash retainer of $7,500 for service as a member of the Compensa
Filing Documents
- d866748d8k.htm (8-K) — 24KB
- 0001193125-24-220529.txt ( ) — 143KB
- kura-20240913.xsd (EX-101.SCH) — 3KB
- kura-20240913_lab.xml (EX-101.LAB) — 18KB
- kura-20240913_pre.xml (EX-101.PRE) — 11KB
- d866748d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 17, 2024 KURA ONCOLOGY, INC. By: /s/ Teresa Bair Teresa Bair Chief Legal Officer